Documentdetail
ID kaart

oai:pubmedcentral.nih.gov:8095...

Onderwerp
Article
Auteur
Rathnasinghe, Raveen Salvatore, Mirella Zheng, Hongyong Jangra, Sonia Kehrer, Thomas Mena, Ignacio Schotsaert, Michael Muster, Thomas Palese, Peter García-Sastre, Adolfo
Langue
en
Editor

Cold Spring Harbor Laboratory

Categorie

biorxiv

Jaar

2021

vermelding datum

16-08-2021

Trefwoorden
influenza live attenuated respiratory δns1
Metriek

Beschrijving

The influenza A non-structural protein 1 (NS1) is known for its ability to hinder the synthesis of type I interferon (IFN) during viral infection.

Influenza viruses lacking NS1 (ΔNS1) are under clinical development as live attenuated human influenza virus vaccines and induce potent influenza virus-specific humoral and cellular adaptive immune responses.

Attenuation of ΔNS1 influenza viruses is due to their high IFN inducing properties, that limit their replication in vivo.

This study demonstrates that pre-treatment with a ΔNS1 virus results in an immediate antiviral state which prevents subsequent replication of homologous and heterologous viruses, preventing disease from virus respiratory pathogens, including SARS-CoV-2.

Our studies suggest that ΔNS1 influenza viruses could be used for the prophylaxis of influenza, SARS-CoV-2 and other human respiratory viral infections, and that an influenza virus vaccine based on ΔNS1 live attenuated viruses would confer broad protection against influenza virus infection from the moment of administration, first by non-specific innate immune induction, followed by specific adaptive immunity.

Rathnasinghe, Raveen,Salvatore, Mirella,Zheng, Hongyong,Jangra, Sonia,Kehrer, Thomas,Mena, Ignacio,Schotsaert, Michael,Muster, Thomas,Palese, Peter,García-Sastre, Adolfo, 2021, Prophylactic protection against respiratory viruses conferred by a prototype live attenuated influenza virus vaccine , Cold Spring Harbor Laboratory

Document

Openen

Delen

Bron

Artikelen aanbevolen door ES/IODE AI

Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial
gravis myasthenia study clinical phase baseline improvement mg-adl 340 week trial placebo period mg maintenance qw